Patient-Centered Drug Delivery and Its Potential Applications for Unmet Medical Needs

References

• Amin AN Deruelle D . Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiol.10 (6), 1049–1062 (2015).
   PubMed Web of Science ®Google Scholar
• Organization WH . Global Status Report on Noncommunicable Diseases 2014. World Health Organization (2014).
   Google Scholar
• Mcmullen CK Safford MM Bosworth HB et al. Patient-centered priorities for improving medication management and adherence. Patient Educ. Couns.98 (1), 102–110 (2015).
   PubMedGoogle Scholar
• Stenholm S Westerlund H Head J et al. Comorbidity and functional trajectories from midlife to old age: the Health and Retirement study. J. Gerontol. A Biol. Sci. Med. Sci.70 (3), 332–338 (2015).
   PubMedGoogle Scholar
• Perfetto EM Burke L Oehrlein EM Epstein RS . Patient-focused drug development: a new direction for collaboration. Med. Care53 (1), 9–17 (2015).
   PubMed Web of Science ®Google Scholar
• Nakamura T . How do we extract solutions of unmet needs from the vast sea of big data? Presented at : 2016 AAAI Spring Symposium Series. Palo Alto, CA, USA (2016).
   Google Scholar
• De La Torre Díez I Cosgaya HM Garcia-Zapirain B López-Coronado M . Big data in health: a literature review from the year 2005. J. Med. Syst.40 (9), 209 (2016).
   PubMedGoogle Scholar
• Breitkreutz J Boos J . Paediatric and geriatric drug delivery. Expert Opin. Drug Deliv.4 (1), 37–45 (2007).
   PubMed Web of Science ®Google Scholar
• Raoof AA Aerssens J . Patient-centered drug discovery as the means to improved R&D productivity. Drug Discov. Today20 (9), 1044–1048 (2015).
   PubMedGoogle Scholar
• Visser JC Woerdenbag HJ Hanff LM Frijlink HW . Personalized medicine in pediatrics: the clinical potential of orodispersible films. AAPS PharmSciTech18 (2), 267–272 (2017).
   PubMed Web of Science ®Google Scholar
• Matsui D . Current issues in pediatric medication adherence. Paediatr. Drugs9 (5), 283–288 (2007).
   PubMedGoogle Scholar
• Wahlich J Stegemann S Orlu-Gul M . Meeting commentary–medicines for older adults: learning from practice to develop patient centric drug products. Int. J. Pharm.456 (1), 251–257 (2013).
   PubMedGoogle Scholar
• Stegemann S Ternik RL Onder G Khan MA Van Riet-Nales DA . Defining patient centric pharmaceutical drug product design. AAPS J.18 (5), 1047–1055 (2016).
   PubMed Web of Science ®Google Scholar
• Liu F Ranmal S Batchelor HK et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs74 (16), 1871–1889 (2014).
   PubMed Web of Science ®Google Scholar
• Hanning SM Lopez FL Wong IC Ernest TB Tuleu C Orlu Gul M . Patient centric formulations for paediatrics and geriatrics: similarities and differences. Int. J. Pharm.512 (2), 355–359 (2016).
   PubMedGoogle Scholar
• Smith RB . Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov. Today Ther. Strateg.8 (3), 131–137 (2012).
   Google Scholar
• Tormay P . Big data in pharmaceutical R&D: creating a sustainable R&D engine. Pharmaceut. Med.29 (2), 87–92 (2015).
   PubMedGoogle Scholar
• Groves P Kayyali B Knott D Kuiken SV . The ‘big data’ revolution in healthcare: accelerating value and innovation (2013).
   Google Scholar
• Park K . Controlled drug-delivery systems: past forward and future back. J. Control. Rel.190, 3–8 (2014).
   PubMed Web of Science ®Google Scholar
• Wang B Hu L Siahaan TJ . Drug delivery: Principles and Applications. John Wiley & Sons Commercial Service, Beijing, China (2016).
   Google Scholar
• Choi YH Chin Y-W Yang SJ et al. Isolation of a lignan-enriched fraction from Schisandra chinensis and its effective solubilization via poloxamer 407-based solid dispersion formulation. J. Pharm. Investig.46 (2), 133–138 (2016).
   Google Scholar
• Ghosh B Ray S Das M . Formulation, development and optimization of mouth dissolving tablets of Rizatriptan benzoate. J. Pharm. Investig.45 (6), 593–600 (2015).
   Google Scholar
• Kim S Gupta B Moon C et al. Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. J. Pharm. Investig.46 (6), 583–592 (2016).
   Google Scholar
• Vasconcelos T Sarmento B Costa P . Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today12 (23), 1068–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Eedara BB Veerareddy PR Jukanti R Bandari S . Improved oral bioavailability of fexofenadine hydrochloride using lipid surfactants: ex vivo, in situ and in vivo studies. Drug Dev. Ind. Pharm.40 (8), 1030–1043 (2014).
   PubMed Web of Science ®Google Scholar
• Wei Y Ye X Shang X et al. Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug-delivery system (S-SEDDS). Colloids Surf. A. Physicochem. Eng. Asp.396, 22–28 (2012).
   Web of Science ®Google Scholar
• Tran PH-L Tran TT-D Piao ZZ et al. Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion. Int. J. Pharm.450 (1), 79–86 (2013).
   PubMedGoogle Scholar
• Kim MS Kim JS Cho W et al. Supersaturatable formulations for the enhanced oral absorption of sirolimus. Int. J. Pharm.445 (1–2), 108–116 (2013).
   PubMedGoogle Scholar
• He W Yang K Fan L et al. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability. Int. J. Pharm.495 (1), 9–18 (2015).
   PubMed Web of Science ®Google Scholar
• Gaur PK Mishra S Bajpai M Mishra A . Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. Biomed. Res. Int.2014, 1–9 (2014).
   Web of Science ®Google Scholar
• Sarnes A Kovalainen M Häkkinen MR et al. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. J. Control Rel.180, 109–116 (2014).
   PubMedGoogle Scholar
• Vo CL Park C Lee BJ . Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm.85 (3 Pt B), 799–813 (2013).
   PubMed Web of Science ®Google Scholar
• Shergill M Patel M Khan S Bashir A Mcconville C . Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int. J. Pharm.497 (1–2), 3–11 (2016).
   PubMed Web of Science ®Google Scholar
• Nguyen TN-G Tran PH-L Van Vo T Duan W Tran TT-D . Development of a sustained release solid dispersion using swellable polymer by melting method. Pharm. Res.33 (1), 102–109 (2016).
   PubMedGoogle Scholar
• Tran TT-D Tran PH-L . Investigation of polyethylene oxide-based prolonged release solid dispersion containing isradipine. J. Drug Deliv. Sci. Technol.23 (3), 269–274 (2013).
   Google Scholar
• Marupudi NI Han JE Li KW Renard VM Tyler BM Brem H . Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf.6 (5), 609–621 (2007).
   PubMed Web of Science ®Google Scholar
• Ma P Mumper RJ . Paclitaxel nano-delivery systems: a comprehensive review. J. Nanomed. Nanotechnol.4 (2), 1000164 (2013).
   PubMedGoogle Scholar
• Green M Manikhas G Orlov S et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol.17 (8), 1263–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Hajek R Vorlicek J Slavik M . Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma43 (3), 141–154 (1996).
   PubMedGoogle Scholar
• Salunke S Giacoia G Tuleu C . The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-A need assessment study. Int. J. Pharm.435 (2), 101–111 (2012).
   PubMedGoogle Scholar
• Salunke S Brandys B Giacoia G Tuleu C . The STEP (safety and toxicity of excipients for paediatrics) database: part 2–the pilot version. Int. J. Pharm.457 (1), 310–322 (2013).
   PubMed Web of Science ®Google Scholar
• Tsuyuki S Senda N Kanng Y et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a Phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast. Cancer. Res. Treat.160 (1), 61–67 (2016).
   PubMedGoogle Scholar
• Peng L Bu Z Ye X Zhou Y Zhao Q . Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur. J. Cancer Care (Engl.) doi:10.1111/ecc.12407 (2015).
   Google Scholar
• Stegemann S . The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution. Eur. J. Pharm. Sci.90, 8–13 (2016).
   PubMedGoogle Scholar
• Stegemann S . Towards better understanding of patient centric drug product development in an increasingly older patient population. Int. J. Pharm.512 (2), 334–342 (2016).
   PubMedGoogle Scholar
• Ernest TB Elder DP Martini LG Roberts M Ford JL . Developing paediatric medicines: identifying the needs and recognizing the challenges. J. Pharm. Pharmacol.59 (8), 1043–1055 (2007).
   PubMed Web of Science ®Google Scholar
• Ivanovska V Rademaker CM Van Dijk L Mantel-Teeuwisse AK . Pediatric drug formulations: a review of challenges and progress. Pediatrics134 (2), 361–372 (2014).
   PubMed Web of Science ®Google Scholar
• Kakodkar K Schroeder JW Jr . Pediatric dysphagia. Pediatr. Clin. North Am.60 (4), 969–977 (2013).
   PubMedGoogle Scholar
• Preis M . Orally disintegrating films and mini-tablets–innovative dosage forms of choice for pediatric use. AAPS PharmSciTech.16 (2), 234–241 (2015).
   PubMed Web of Science ®Google Scholar
• Lopez FL Ernest TB Tuleu C Gul MO . Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert. Opin. Drug. Deliv.12 (11), 1727–1740 (2015).
   PubMed Web of Science ®Google Scholar
• Santoveña A Hernández-Paiz Z Fariña J . Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int. J. Pharm.423 (2), 360–364 (2012).
   PubMedGoogle Scholar
• Stoltenberg I Breitkreutz J . Orally disintegrating mini-tablets (ODMTs)–a novel solid oral dosage form for paediatric use. Eur. J. Pharm. Biopharm.78 (3), 462–469 (2011).
   PubMed Web of Science ®Google Scholar
• Walsh J Bickmann D Breitkreutz J Chariot-Goulet M , European Paediatric Formulation I. Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int. J. Pharm.415 (1–2), 221–231 (2011).
   PubMed Web of Science ®Google Scholar
• Krause J Breitkreutz J . Improving drug delivery in paediatric medicine. Pharm. Med.22 (1), 41–50 (2008).
   Google Scholar
• Breitkreutz J Boos J . Paediatric and geriatric drug delivery. Expert. Opin. Drug. Deliv.4 (1), 37–45 (2007).
   PubMed Web of Science ®Google Scholar
• Kearns GL Abdel-Rahman SM Alander SW Blowey DL Leeder JS Kauffman RE . Developmental pharmacology–drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349 (12), 1157–1167 (2003).
   PubMed Web of Science ®Google Scholar
• Meibohm B Beierle I Derendorf H . How important are gender differences in pharmacokinetics?Clin. Pharmacokinet.41 (5), 329–342 (2002).
   PubMed Web of Science ®Google Scholar
• Taupitz T Dressman JB Klein S . New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Eur. J. Pharm. Biopharm.84 (1), 208–218 (2013).
   PubMed Web of Science ®Google Scholar
• Bangalore S Kamalakkannan G Parkar S Messerli FH . Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120 (8), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Park H-S Han J-H Jung S-H Jo E-J Myung C-S . The combination of valsartan and ramipril protects against blood vessel injury and lowers blood pressure. J. Pharm. Investig.46 (3), 265–272 (2016).
   Google Scholar
• García-Pérez L-E Lvarez M Dilla T Gil-Guillén V Orozco-Beltrán D . Adherence to therapies in patients with Type 2 diabetes. Diabetes Ther.4 (2), 175–194 (2013).
   PubMed Web of Science ®Google Scholar
• Taylor BA Lorson L White CM Thompson PD . A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis238 (2), 329–335 (2015).
   PubMed Web of Science ®Google Scholar
• Bell DS . Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes. Metab.15 (4), 291–300 (2013).
   PubMed Web of Science ®Google Scholar
• Shishoo CJ Shah SA Rathod IS Savale SS Vora MJ . Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm.228 (1–2), 53–67 (2001).
   PubMedGoogle Scholar
• Singh S Bhutani H Mariappan T . Quality problems of anti-tuberculosis fixed-dose combinations (FDCS): a way forward. Indian. J. Tuberc.53, 201–205 (2006).
   Google Scholar
• Mitra A Wu Y . Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J.14 (3), 646–655 (2012).
   PubMedGoogle Scholar
• Lopez FL Ernest TB Tuleu C Gul MO . Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin. Drug Deliv.12 (11), 1727–1740 (2015).
   PubMed Web of Science ®Google Scholar
• Stovitz SD Johnson RJ . NSAIDs and musculoskeletal treatment: what is the clinical evidence?Phys. Sportsmed.31 (1), 35–52 (2003).
   PubMed Web of Science ®Google Scholar
• Podichetty VK Mazanec DJ Biscup RS . Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention. Postgrad. Med. J.79 (937), 627–633 (2003).
   PubMed Web of Science ®Google Scholar
• Stovitz SD Johnson RJ . NSAIDs and musculoskeletal treatment: what is the clinical evidence?Phys. Sportsmed.31 (1), 35–52 (2003).
   PubMed Web of Science ®Google Scholar
• Mccarberg B Gibofsky A . Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin. Ther.34 (9), 1954–1963 (2012).
   PubMed Web of Science ®Google Scholar
• Bae SK Kim SH Lee HW et al. Pharmacokinetics of a new once-daily controlled-release formulation of aceclofenac in Korean healthy subjects compared with immediate-release aceclofenac and the effect of food: a randomized, open-label, three-period, crossover, single-centre study. Clin. Drug Investig.32 (2), 111–119 (2012).
   PubMedGoogle Scholar
• Kang W-H Van Nguyen H Park C Choi Y-W Lee B-J . Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet. Eur. J. Pharm. Sci.102, 85–93 (2017).
   PubMed Web of Science ®Google Scholar
• Haberer J Mellins C . Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep.6 (4), 194–200 (2009).
   PubMedGoogle Scholar
• Mennella JA Spector AC Reed DR Coldwell SE . The bad taste of medicines: overview of basic research on bitter taste. Clin. Ther.35 (8), 1225–1246 (2013).
   PubMed Web of Science ®Google Scholar
• Porche DJ . Tenofovir disoproxil fumarate (Viread™). J. Assoc. Nurses AIDS Care13 (3), 100–102 (2002).
   PubMedGoogle Scholar
• Mapelli L Fabiani F Boltri L Gatti P Serratoni M Cassanmagnago R . Fexofenadine microcapsules and compositions containing them. US8580313 B2 (2013).
   Google Scholar
• Golzi R Boltri L Stollberg C . Microcapsules by coacervation containing a pharmaceutical incorporated in the coating polymer. US20130156934 A1 (2013).
   Google Scholar
• Kaushik D Dureja H . Recent patents and patented technology platforms for pharmaceutical taste masking. Recent Pat. Drug Deliv. Formul8 (1), 37–45 (2014).
   PubMedGoogle Scholar
• Lai JW Qian K Venkatesh G . Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane. EP 1809251 B1 (2012).
   Google Scholar
• Fitzpatrick J . Drug encapsulation for patient-centric dosing. Pharm. Technol38 (4), 28–32 (2014).
   Google Scholar
• Douroumis D . Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin. Drug Deliv.8 (5), 665–675 (2011).
   PubMed Web of Science ®Google Scholar
• Douroumis D . Practical approaches of taste masking technologies in oral solid forms. Expert Opin. Drug Deliv.4 (4), 417–426 (2007).
   PubMed Web of Science ®Google Scholar
• Vummaneni V Nagpal D . Taste masking technologies: an overview and recent updates. Int. J. Res. Pharm. Biomed. Sci.3 (2), 510–524 (2012).
   Google Scholar
• Sumiyoshi T Higuchi Y Uehara T . Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav. Neurosci.7, 140 (2013).
   PubMed Web of Science ®Google Scholar
• Jain R Stark JG . Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. Postgrad. Med.128 (7), 672–681 (2016).
   PubMed Web of Science ®Google Scholar
• Dungarwal UN Patil SB . Development of orodispersible tablets of taste masked rizatriptan benzoate using hydroxypropyl β cyclodextrin. J. Pharm. Investig.46 (6), 537–545 (2016).
   Google Scholar
• Refaat A Sokar M Ismail F Boraei N . Tadalafil oral disintegrating tablets: an approach to enhance tadalafil dissolution. J. Pharm. Investig.45 (5), 481–491 (2015).
   Google Scholar
• Matoug Elwerfalli A Ghanchi Z Rashid F Alany RG Elshaer A . New generation of orally disintegrating tablets for sustained drug release: a propitious outlook. Curr. Drug Deliv.12 (6), 652–667 (2015).
   PubMedGoogle Scholar
• Djupesland PG . Nasal drug delivery devices: characteristics and performance in a clinical perspective–a review. Drug Deliv. Transl. Res.3 (1), 42–62 (2013).
   PubMed Web of Science ®Google Scholar
• Wermeling DP Miller JL Archer SM Rayens MK Rudy AC . Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps. J. Clin. Pharmacol.45 (8), 969–973 (2005).
   PubMedGoogle Scholar
• Graff CL Pollack GM . Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci.94 (6), 1187–1195 (2005).
   PubMed Web of Science ®Google Scholar
• Dondeti P Zia H Needham TE . In vivo evaluation of spray formulations of human insulin for nasal delivery. Int. J. Pharm.122 (1), 91–105 (1995).
   Google Scholar
• Andreone P Colombo MG Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterol.147 (2), 359–365 (2014).
   PubMed Web of Science ®Google Scholar
• Graham SM Grzemska M Gie RP . The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. Int. J. Tuberc. Lung Dis.19 (Suppl. 1), 3–8 (2015).
   PubMedGoogle Scholar
• De Cates AN Farr MR Wright N et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst. Rev.4, CD009868 (2014).
   PubMedGoogle Scholar
• Sica DA . Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs62 (3), 443–462 (2002).
   PubMed Web of Science ®Google Scholar
• Dhillon S . Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers. Drugs Aging28 (3), 237–248 (2011).
   PubMedGoogle Scholar
• Deharo P Quilici J Bonnet G et al. Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. Int. J. Cardiol.172 (1), e1–e2 (2014).
   PubMed Web of Science ®Google Scholar
• Koh JS Park Y Tantry US et al. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: the ACCEL-COMBO trial. Platelets doi:10.1080/09537104.2016.1206197, 1–7 (2016) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Jung JA Kim TE Kim JR et al. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study. Clin. Ther.35 (7), 985–994 (2013).
   PubMed Web of Science ®Google Scholar
• Fong SY Ibisogly A Bauer-Brandl A . Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: spray drying versus freeze-drying. Int. J. Pharm.496 (2), 382–391 (2015).
   PubMed Web of Science ®Google Scholar
• Lou H Liu M Wang L et al. Development of a mini-tablet of co-grinded prednisone–neusilin complex for pediatric use. AAPS PharmSciTech14 (3), 950–958 (2013).
   PubMed Web of Science ®Google Scholar
• Stange U Fuhrling C Gieseler H . Taste masking of naproxen sodium granules by fluid-bed coating. Pharm. Dev. Technol.19 (2), 137–147 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang Z Huang J Jiang S et al. Porous starch based self-assembled nano-delivery system improves the oral absorption of lipophilic drug. Int. J. Pharm.444 (1–2), 162–168 (2013).
   PubMedGoogle Scholar
• Khan S Misra SK Sharma N . Formulation and evaluation of multiparticulate gel beads containing tinidazole for stomach specific delivery. Int. J. PharmTech. Res.8 (8), 196–205 (2015).
   Google Scholar
• Shamma R Elkasabgy N . Design of freeze-dried Soluplus/polyvinyl alcohol-based film for the oral delivery of an insoluble drug for the pediatric use. Drug deliv.23 (2), 489–499 (2016).
   PubMed Web of Science ®Google Scholar
• Moon YW Kang SB Kim TK Lee MC . Efficacy and safety of aceclofenac controlled release in patients with knee osteoarthritis: a 4-week, multicenter, randomized, comparative clinical study. Knee Surg. Relat. Res.26 (1), 33–42 (2014).
   PubMedGoogle Scholar
• Lee B-J Park J-B . Emerging oral controlled-release technology for optimal therapy. Therapeutic Delivery Methods: A Concise Overview of Emerging Areas. DormerL ( Ed.). Future Medicine, London, UK, 40–53 (2013).
   Google Scholar
• Aurpibul L Puthanakit T . Review of tenofovir use in HIV-infected children. Pediatr Infect. Dis. J.34 (4), 383–391 (2015).
   PubMed Web of Science ®Google Scholar
• Venkatesh GM Stevens PJ Lai JW . Development of orally disintegrating tablets comprising controlled-release multiparticulate beads. Drug Dev. Ind. Pharm.38 (12), 1428–1440 (2012).
   PubMed Web of Science ®Google Scholar
• Yusuf H Kett V . Current prospects and future challenges for nasal vaccine delivery. Hum. Vaccin. Immunother.13 (1), 34–45 (2017).
   PubMed Web of Science ®Google Scholar
• Zaman M Chandrudu S Toth I . Strategies for intranasal delivery of vaccines. Drug Deliv. Transl. Res.3 (1), 100–109 (2013).
   PubMed Web of Science ®Google Scholar
• Jung Won Tae Choi Youn Woong Nam Kyu Yeol et al. Complex agent containing clopidogrel and aspirin. WO2013065936 A1 (2013).
   Google Scholar